The U.S. Food and Drug Administration (FDA) has issued another warning to Novo Nordisk regarding misleading advertisements for its diabetes drug Ozempic. This is the second such warning in less than a month, as part of a broader FDA crackdown on deceptive drug marketing following President Donald Trump's order for tighter oversight.
Key Takeaways
The FDA has issued its second warning to Novo Nordisk in less than a month for misleading advertisements about its diabetes drug Ozempic. The ad misrepresented the drug's approved uses and implied superiority over other GLP-1 medicines. Additionally, Novo Nordisk plans to sell obesity drugs on Hims & Hers Health platform, ending a recent legal dispute.
The FDA stated that an online ad misrepresented Ozempic's approved uses and implied superiority over other GLP-1 medicines for type 2 diabetes. The commercial suggested all type 2 diabetes patients were eligible for all of Ozempic's indications, even though some approvals apply only to patients with heart disease or chronic kidney disease.
Regulators also noted that the ad's comedic elements created the impression that competing drugs lacked meaningful benefits. Novo Nordisk confirmed receipt of the 'Untitled Letter' from the FDA concerning an advertising campaign for Ozempic, according to spokesperson Liz Skrbkova.
The first warning letter to Novo was issued on February 5 regarding a TV spot for Wegovy, Novo's weight-loss pill. Earlier on Tuesday, the FDA also sent 30 warning letters to telehealth firms over misleading claims about compounded GLP-1 drugs.
In related news, Novo Nordisk plans to sell its obesity drugs on Hims & Hers Health platform, ending a recent legal dispute between the two companies. This partnership comes nearly a month after Novo sued Hims over patent infringement following the launch and subsequent cancellation of a $49 copy of Novo's obesity pill. The FDA had also threatened action against Hims.
How this summary was created
This summary synthesizes reporting from 6 independent publishers using AI. All sources are cited and linked below. NewsBalance is a news aggregator and media literacy tool, not a news publisher. AI-generated content may contain errors or inaccuracies — always verify important information with the original sources.